Are Regeneron’s Libtayo hopes ‘hubris’ or can it really dominate I-O combos?

6th November 2019 Uncategorised 0

Regeneron’s sixth-to-market PD-1 inhibitor Libtayo has been slow to catch on, but the company hopes to make headway in new markets and with combination immuno-oncology regimens. But analysts aren’t optimistic about the drug’s growth prospects, and newly released data isn’t calming their fears.

More: Are Regeneron’s Libtayo hopes ‘hubris’ or can it really dominate I-O combos?
Source: fierce